CagriSema (Investigational)

CagriSema is Novo Nordisk's answer to tirzepatide's dual-agonism: a fixed-dose combination of semaglutide (the proven GLP-1 agonist from Wegovy) and cagrilintide, a novel amylin receptor agonist. Amylin is a pancreatic hormone co-secreted with insulin that signals satiety through the brain's area postrema, slowing gastric emptying and reducing meal size through pathways distinct from GLP-1. By combining two complementary satiety mechanisms — GLP-1 and amylin — CagriSema aims to achieve additive appetite suppression without requiring glucagon receptor activation. The REDEFINE-1 Phase 3 trial produced a 22.7 percent mean weight loss, with a remarkable 60 percent of participants achieving 20 percent or greater body weight reduction — a threshold that historically required bariatric surgery. Novo Nordisk filed with the FDA in December 2025, placing potential US approval on a timeline of late 2026 to mid-2027 depending on review speed and any additional data requests. The combination of semaglutide's proven cardiovascular profile from SELECT with the additive amylin mechanism makes CagriSema one of the more compelling pipeline agents: it is not merely incremental but represents a meaningfully different physiological approach. The semaglutide component should inherit some cardiovascular benefit signals from existing SELECT data, though CagriSema-specific CV outcomes will require its own trial. Weekly subcutaneous injection is expected to be the delivery method, consistent with semaglutide's established pen infrastructure. Pricing has not been announced, but Novo Nordisk's existing NovoCare programs suggest competitive patient assistance will be available. CagriSema is positioned to compete directly with tirzepatide at the top of the approved efficacy table once it clears regulatory review.